Prelude Therapeutics Presents Strong Preclinical Data for Lead Cancer Candidate PRT13722

summarizeSummary

Prelude Therapeutics presented strong preclinical data for its lead cancer candidate, PRT13722, showing durable tumor regressions and an improved safety profile, with an IND filing expected mid-2026.

check_boxKey Events

• Preclinical Data Presentation

  Prelude Therapeutics presented new preclinical data for PRT13722, a lead development candidate for HR+/HER2- breast cancer, at the AACR Annual Meeting 2026.

• Strong Efficacy Profile

  PRT13722 demonstrated durable complete tumor regressions as a monotherapy in xenograft models and synergistic activity with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.

• Improved Safety Profile

  The data indicated an improved preclinical hematological safety profile for PRT13722 compared to dual KAT6A/B inhibitors like prifetrastat.

• Advancing to Clinic

  The company remains on track for an Investigational New Drug (IND) filing in mid-2026, with a Phase 1 study anticipated in the second half of 2026.

auto_awesomeAnalysis

Prelude Therapeutics announced compelling preclinical data for PRT13722, its lead development candidate for HR+/HER2- breast cancer, at the AACR Annual Meeting. The data highlights PRT13722's potential as a first-in-class, highly selective KAT6A degrader, demonstrating durable complete tumor regressions as a monotherapy and synergistic activity with standard-of-care agents. Crucially, it shows an improved safety profile compared to existing inhibitors, addressing a key challenge in cancer therapy. This positive update significantly de-risks the program as the company prepares for an IND filing in mid-2026 and Phase 1 study initiation in the second half of 2026, reinforcing its pipeline strength and future growth prospects in a large market.